Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T19:18:47.713Z.
Calculation as of: 2026-10-06T19:18:47.713Z.
Quote observation: 2026-10-06T19:15:29.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 03e1a7bc6a4900f8947eb756f3a7beb4b36797f74791bf8fa7d12ffa125de730
PE RATIO
N/A
Market Cap
$5.05B
PE Ratio
34.98
TTM Avg
36.67
3Y Avg
43.17
5Y Avg
53.01
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | $5.18B | N/A | N/A | N/A | N/A |
| Sotera Health Company (SHC)vs › | $5.21B | 31.89 | 70.23 | 85.34 | 112.40 |
| Cogent Biosciences, Inc. (COGT)vs › | $5.14B | N/A | N/A | N/A | N/A |
| CRISPR Therapeutics AG (CRSP)vs › | $5.24B | N/A | 17.47 | 59.21 | 59.21 |
| Scholar Rock Holding Corporation (SRRK)vs › | $5.11B | N/A | N/A | N/A | N/A |
| Doximity, Inc. (DOCS)vs › | $5.25B | 33.01 | 29.46 | 43.55 | 46.11 |
| Merit Medical Systems, Inc. (MMSI)vs › | $5.05B | 34.98 | 36.67 | 43.17 | 53.01 |
| PTC Therapeutics, Inc. (PTCT)vs › | $5.31B | N/A | 8.39 | 8.39 | 8.39 |
| Waystar Holding Corp. (WAY)vs › | $5.00B | 37.28 | 43.03 | 91.22 | 91.22 |
| Erasca, Inc. (ERAS)vs › | $4.94B | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$55.69
Forward EPS (Est.)
$-0.03
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
